12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

GW Pharma, Otsuka Pharmaceutical preclinical data

In mice, >=50 mg/kg CBDV significantly reduced maximal electroshock-induced seizures and >=100 mg/kg CBDV significantly reduced audiogenic-induced seizures. In rats, >=100 mg/kg CBDV significantly reduced pentylenetetrazole-induced seizures. CBDV...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >